UnknownPhase 2NCT00247260
Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma
Studying Rare tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- pSiVida Limited
- Principal Investigator
- Pierce ChowSingapore General Hospital
- Intervention
- 32P BioSilicon(device)
- Enrollment
- 50 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2007
Study locations (1)
- Singapore General Hospital, Outram Road, Singapore
Collaborators
pSiOncology Private Limited
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00247260 on ClinicalTrials.govOther trials for Rare tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07356531Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver CancerJIANGSU SHENMING Medical Technology CO., Ltd
- ACTIVE NOT RECRUITINGNCT04145141National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT02984566Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)University of Sydney
See all trials for Rare tumor of liver and intrahepatic biliary tract →